Medical Stocks

Zimmer Holdings Analysis – June 2015 Update $ZMH

Zimmer_Logo_2012Zimmer Holdings (ZMH) has shown some earnings growth over the last few years, which may garner some attention from prospective investors. In addition, the company’s acquisition of competitor Biomet will be completed in the very near future. Not all analysts are of the view this acquisition will be good for the company, though, as Seeking Alpha contributor Henry Elrod believes the merger will make the company bigger, but not necessarily better.

Considering the merger is a great qualitative item to utilize when making an investment decision; however, Benjamin Graham, the father of value investing, taught that the most important aspect to consider is whether the company is trading at a discount relative to its intrinsic value. It is through a thorough fundamental analysis that the investor is able to make a determination about a potential investment’s merits.

The model is inspired by the teachings of Benjamin Graham and considers numerous metrics intended to help the investor reduce risk levels. The first part of the analysis is to determine whether the company is suitable for the very conservative Defensive Investor or the less conservative Enterprising Investor, who is willing to spend a greater amount of time conducting further research.

In addition, Graham strongly suggested that investors avoid speculation in order to remove the subjective elements of emotion. This is best achieved by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another. By using theModernGraham method, one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.

ZMH Chart

ZMH data by YCharts

To read the rest of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Defensive Investor – Must pass at least 6 of the following 7 tests: Score = 4/7

  1. Adequate Size of Enterprise – Market capitalization of at least $2 billion – PASS
  2. Sufficiently Strong Financial Condition – Current ratio greater than 2 – PASS
  3. Earnings Stability – Positive earnings per share for at least 10 straight years – PASS
  4. Dividend Record – Has paid a dividend for at least 10 straight years – FAIL
  5. Earnings Growth – Earnings per share has increased by at least one-third over the last 10 years, using three-year averages at the beginning and end of the period – PASS
  6. Moderate PEmg (price over normalized earnings) Ratio – PEmg is less than 20 – FAIL
  7. Moderate Price-to-Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 – FAIL

Enterprising Investor – Must pass at least 4 of the following 5 tests to be suitable for a Defensive Investor: Score = 5/5

  1. Sufficiently Strong Financial Condition, Part 1 – Current ratio greater than 1.5 – PASS
  2. Sufficiently Strong Financial Condition, Part 2 – Debt-to-Net Current Assets ratio less than 1.1 – PASS
  3. Earnings Stability – Positive earnings per share for at least 5 years – PASS
  4. Dividend Record – Currently pays a dividend – PASS
  5. Earnings Growth – EPSmg greater than that 5 years ago – PASS

Valuation Summary

Key Data

Recent Price $113.19
MG Value $80.22
MG Opinion Overvalued
Value Based on 3% Growth $69.90
Value Based on 0% Growth $40.98
Market-Implied Growth Rate 7.49%
NCAV $7.57
PEmg 23.48
Current Ratio 13.11
PB Ratio 2.97

Balance Sheet – March 2015

Current Assets $11,917,000,000
Current Liabilities $909,000,000
Total Debt $9,061,000,000
Total Assets $17,190,000,000
Intangible Assets $2,995,000,000
Total Liabilities $10,609,000,000
Outstanding Shares 172,900,000

Earnings Per Share

2015 (estimate) $5.93
2014 $4.19
2013 $4.43
2012 $4.29
2011 $4.03
2010 $2.97
2009 $3.32
2008 $3.72
2007 $3.26
2006 $3.40
2005 $2.93

Earnings Per Share – ModernGraham

2015 (estimate) $4.82
2014 $4.17
2013 $4.04
2012 $3.79
2011 $3.51
2010 $3.28

Dividend History

ZMH Dividend Chart

ZMH Dividend data by YCharts

Competitive Comparison

Zimmer Holdings is not very attractive when compared to some of its competitors. For example, ModernGraham valuations of both Edwards Lifesciences (NYSE:EW) and C.R. Bard (NYSE:BCR) indicate both of those companies are suitable for the Enterprising Investor, and both are fairly valued at the present time.


Zimmer Holdings passes the initial requirements of the Enterprising Investor but not the Defensive Investor. Specifically, the Defensive Investor is concerned by the short dividend history and the high PEmg and PB ratios while the Enterprising Investor has no initial concerns. As a result, all Enterprising Investors should feel very comfortable proceeding to the next part of the analysis, which is a determination of the company’s intrinsic value.

When it comes to that valuation, it is critical to consider the company’s earnings history. In this case, it has grown its EPSmg (normalized earnings) from $3.51 in 2011 to an estimated $4.82 for 2015. This level of demonstrated growth does not support the market’s implied estimate for annual earnings growth of 7.49% over the next 7-10 years.

In recent years, the company’s actual growth in EPSmg has averaged around 5.43% annually, but the ModernGraham valuation model reduces the actual growth to a more conservative figure when making an estimate, and returns an estimate of intrinsic value well below the current price, indicating that Zimmer Holdings is overvalued at the present time.

Disclaimer:  The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.


Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top